Evicenter
MarkdownMedical informationP&T meetings
Cretostimogene grenadenorepvec (CG0070)

BCG-unresponsive high-risk non-muscle-invasive bladder cancer

Manufacturer
CG Oncology
Launch
Not announced
Last updated
161 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of BCG-unresponsive high-risk non-muscle-invasive bladder cancer

Economic impact of BCG-unresponsive high-risk non-muscle-invasive bladder cancer on families

7 evidence topics · 7 sources

Financial toxicity after radical cystectomy versus bladder-sparing therapy

“Financial toxicity was measured with the Comprehensive Score for Financial Toxicity (COST),” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“which includes questions about concern with covering the costs of treatment, out-of-pocket expenses, ability to work, and impact and worry about finances. COST scores range from 0 to 44, with lower scores indicating greater financial distress.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Participants in the BST arm reported significantly higher financial toxicity and financial difficulties 12 months after enrollment than participants in the RC arm.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Participants in the BST and RC arms endorsed similar financial burden at enrollment. However, by 12 months, participants in the RC arm experienced lower financial difficulties and lower financial toxicity. Although RC is a morbid surgery with a high initial burden, after recovery, those patients mostly experience low health care utilization. Conversely, patients undergoing BST have several induction and maintenance treatments in the year after their recurrence coupled with quarterly surveillance cystoscopies. The financial burden of BST may increase going forward, given recent US Food and Drug Administration approvals of nadofaragene and nogapendekin for BCG-unresponsive NMIBC, which are substantially more expensive than currently available BSTs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote